EFG International AG Purchases New Shares in Cogent Biosciences, Inc. $COGT

Posted by Francis Steltz on Aug 27th, 2026

EFG International AG acquired a new stake in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 87,739 shares of the technology company’s stock, valued at approximately $3,396,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Pier Capital LLC bought a new stake in shares of Cogent Biosciences during the fourth quarter worth $1,643,000. Vanguard Group Inc. boosted its holdings in Cogent Biosciences by 48.4% in the fourth quarter. Vanguard Group Inc. now owns 11,514,326 shares of the technology company’s stock valued at $408,989,000 after acquiring an additional 3,756,664 shares during the last quarter. Pictet Asset Management Holding SA boosted its holdings in Cogent Biosciences by 710.7% in the fourth quarter. Pictet Asset Management Holding SA now owns 112,476 shares of the technology company’s stock valued at $4,232,000 after acquiring an additional 98,602 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new stake in Cogent Biosciences in the fourth quarter worth about $1,330,000. Finally, SEB Asset Management AB acquired a new stake in Cogent Biosciences in the first quarter worth about $6,329,000.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Piper Sandler boosted their price objective on Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Guggenheim lifted their price target on shares of Cogent Biosciences from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Wednesday, July 8th. Wall Street Zen raised shares of Cogent Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Finally, Wedbush restated an “outperform” rating and issued a $55.00 price objective on shares of Cogent Biosciences in a report on Friday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $49.40.

View Our Latest Stock Report on COGT

Cogent Biosciences Stock Down 0.2%

Shares of Cogent Biosciences stock opened at $36.72 on Thursday. The company has a quick ratio of 13.57, a current ratio of 13.57 and a debt-to-equity ratio of 0.48. Cogent Biosciences, Inc. has a 12 month low of $11.60 and a 12 month high of $43.73. The business has a fifty day simple moving average of $38.69 and a 200 day simple moving average of $36.62. The stock has a market cap of $6.37 billion, a PE ratio of -17.00 and a beta of 0.38.

Cogent Biosciences (NASDAQ:COGT – Get Free Report) last released its earnings results on Monday, August 10th. The technology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.03. Research analysts predict that Cogent Biosciences, Inc. will post -2.24 EPS for the current year.

Cogent Biosciences Company Profile

(Free Report)

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.